Drug Trial Radar · NCT02187471
Treatment of Pain Associated With Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Nov 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,301
Actual
Start
Jan 16, 2015
Primary completion
Jan 6, 2017
Study completion Jan 12, 2017
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Jul 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 hours.
Conditions
- Pain Associated With Fibromyalgia
Interventions
DS-5565Drug
DS-5565 15 mg QD or BID; tablet for oral use
PregabalinDrug
Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
Placebo tabletDrug
Placebo tablet for oral use, matching DS-5565 tablet
Placebo capsuleDrug
Placebo capsule for oral use, matching pregabalin capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or PlaceboTime frame: Baseline up to Week 13 postdose
Locations
154 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Anaheim, California
Site not named
Covina, California
Site not named
El Cajon, California
Site not named
Encino, California
Site not named
Huntington Beach, California
Site not named
Lakewood, California
Site not named
Lomita, California
Site not named
Los Angeles, California
Site not named
National City, California
Site not named
Northridge, California
Site not named
Oceanside, California
Site not named
Sacramento, California
Site not named
Upland, California
Site not named
Walnut Creek, California
Site not named
Boca Raton, Florida
Site not named
DeLand, Florida
Site not named
Edgewater, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Fort Myers, Florida
Site not named
Hialeah, Florida
Site not named
Largo, Florida
Site not named
Lauderdale Lakes, Florida
Site not named
Maitland, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Sunrise, Florida
Site not named
Tamarac, Florida
Site not named
Tampa, Florida
Site not named
Vero Beach, Florida
Site not named
West Palm Beach, Florida
Site not named
Winter Haven, Florida
Site not named
Winter Park, Florida
Site not named
Dawsonville, Georgia
Site not named
Marietta, Georgia
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.